{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Study schematic', 'Run-in (4 weeks)', 'UMEC/VI62.5/25mcg( (QD)', 'Pre-', 'COPD Meds*', 'Screen', 'R', 'UMEC62.5 mcg (QD)', 'Follow-up phone call', '7+ 3 days', 'Salmeterol 50mcg (BID)', 'V0', 'V1', 'V2', 'V3', 'V4', 'V5', 'V6', 'W4', 'W12', 'W24', '24 Week Treatment Period', '*Inhaled COPD medications including LABAs, LAMAs or LABA/LAMA combination products are', 'allowed in run-in. ICS alone or in combination with a bronchodilator or any exclusionary', 'medications are not allowed.', 'Type and Number of Subjects', 'Approximately 3232 subjects will be screened, such that 2424 subjects will be', 'randomized and approximately 2181 evaluable subjects complete the study.', 'Analysis', 'The primary purpose of this study is to demonstrate improvements in lung function for', 'subjects treated with UMEC/VI compared with UMEC for 24 weeks.', 'The primary endpoint is change from baseline in trough FEV1 at Week 24.', 'The null hypothesis is no difference between treatment groups (HO: T - S = 0), with', 'the alternative hypothesis that there is a difference between treatment groups (H1: T -', 'S # 0), where T is the mean change from baseline for UMEC/VI and S is the mean', 'change from baseline for UMEC.', 'The primary endpoint of mean change from baseline in trough FEV, at the end of Week', '24 will be analysed using Mixed Models repeated Measures (MMRM) analysis. The', 'MMRM analysis will include measurements at Treatment Weeks 4, 12 and 24. Treatment', 'group (a categorical variable) will be fitted as the explanatory variable with appropriate', 'pre-defined variables, stratum (number of bronchodilators per day during run-in) and', 'baseline values, fitted as covariates. Visit (nominal) will be fitted as a categorical variable', 'and visit-by-baseline and visit-by-treatment interaction terms will be included to allow', 'treatment effects to be estimated at each visit separately. The variance covariance matrix', '13']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'will be assumed to be unstructured (based on previous experience no issues are expected', 'with fitting models with this matrix structure).', 'The estimated treatment differences between UMEC/VI versus UMEC for each endpoint', 'will be presented with the 95% confidence intervals for the difference and the p-value.', '2.', 'INTRODUCTION', '2.1.', 'Study Rationale', 'Chronic obstructive pulmonary disease (COPD) is associated with poor health-related', 'quality of life (HRQoL). Pharmacologic therapy is used to improve lung function, reduce', 'symptoms, frequency and severity of exacerbations, and improve patients HRQoL', '[GOLD, 2015]. Umeclidinium/Vilanterol (UMEC/VI 62.5/25 mcg) is indicated for the', 'maintenance treatment of COPD that contain long-acting muscarinic antagonist (LAMA)', 'and long-acting beta2-agonist (LABA) bronchodilators. Umeclidinium (UMEC) is', 'indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients', 'with COPD. Salmeterol has long been used for symptoms management of COPD.', 'However, a direct comparison of these maintenance therapies has not been conducted', 'with respect to HRQoL.', 'The primary purpose of this study is to demonstrate improvements in lung function for', 'subjects treated with UMEC/VI compared with UMEC for 24 weeks. The effect of', 'UMC/VI, UMEC, and salmeterol with respect to patient HRQoL measured through', 'patient reported outcomes (PROs) questionnaires, symptoms and lung function will also', 'be evaluated.', '2.2.', 'Brief Background', 'COPD is characterized by an airflow limitation which is not fully reversible, usually', 'progressive and accompanied by a chronic cough, sputum production and dyspnea which', 'can be a major cause of disability and anxiety associated with the disease [Maleki-Yazdi,', '2014]', 'Furthermore, acute exacerbations contribute to the overall severity of disease as these', 'episodes are accompanied by worsened symptoms and are associated with increased', 'decline in lung function and mortality [Wedzicha, 2013; Schmidt, 2014].', 'Pharmacologic therapy is used to improve lung function, reduce symptoms, reduce the', 'frequency and severity of exacerbations, and also to improve health status and exercise', 'tolerance. Maintenance treatment is recommended primarily through the use of LABAs', 'or LAMAs. COPD treatment guidelines recommend an incremental approach to', 'pharmacological treatment as the disease state worsens, involving the use of', 'combinations of drug classes with different or complementary mechanisms [GOLD,', '2015].', 'UMEC/VI inhalation powder is a combination of UMEC (umeclidinium bromide), a', 'LAMA, and VI (Vilanterol), a LABA, delivered via the ELLIPTA dry powder inhaler', '14']\n\n###\n\n", "completion": "END"}